This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KMPH Zevra Therapeutics (KMPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zevra Therapeutics Stock (NASDAQ:KMPH) 30 days 90 days 365 days Advanced Chart Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$4.48▼$6.2752-Week Range N/AVolume64,100 shsAverage Volume189,500 shsMarket Capitalization$200.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL. Read More Receive KMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KMPH Stock News HeadlinesHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy RecommendationJuly 2, 2025 | msn.comThis Crypto Is Set to Explode in JanuaryThis Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.August 2 at 2:00 AM | Crypto 101 Media (Ad)Zevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reachMay 14, 2025 | msn.comZevra Therapeutics closes sale of Rare Disease PRV for $150MApril 8, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $25 from $23 at CanaccordMarch 13, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $22 from $20 at GuggenheimMarch 13, 2025 | markets.businessinsider.comZevra Therapeutics reports Q4 EPS (67c), consensus (40c)March 12, 2025 | markets.businessinsider.comSee More Headlines KMPH Stock Analysis - Frequently Asked Questions How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:KMPH) posted its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). Zevra Therapeutics had a negative net margin of 328.56% and a negative trailing twelve-month return on equity of 16.12%. When did Zevra Therapeutics IPO? Zevra Therapeutics (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Meta Platforms (META), SCYNEXIS (SCYX), BioCryst Pharmaceuticals (BCRX), Zoom Communications (ZM) and TherapeuticsMD (TXMD). Company Calendar Last Earnings3/30/2022Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KMPH CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees22Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.56 million Net Margins-328.56% Pretax Margin-335.26% Return on Equity-16.12% Return on Assets-14.17% Debt Debt-to-Equity Ratio0.14 Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$10.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow23.28 Book Value$3.63 per share Price / BookN/AMiscellaneous Outstanding Shares34,505,000Free Float34,125,000Market Cap$200.47 million OptionableOptionable Beta2.16 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:KMPH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.